A multiplex platform for the identification of ovarian cancer biomarkers.

Kristin L M BoylanKate GeschwindJoseph S KoopmeinersMelissa A GellerTimothy K StarrAmy P N Skubitz

Published in: Clinical proteomics (2017)

These data demonstrate that the Proseek® technology can replicate the results established by conventional clinical assays for known biomarkers, identify new candidate biomarkers, and improve the sensitivity and specificity of CA125 alone. Additional studies using a larger cohort of patients will allow for validation of these biomarkers and lead to the development of a screening tool for detecting early stage ovarian cancer in the general population.

Keyphrases

early stage
high throughput
ejection fraction
end stage renal disease
newly diagnosed
radiation therapy
sentinel lymph node
locally advanced